Genetic Predisposition to Numerous Large Ulcerating Basal Cell Carcinomas and Response to Immune Therapy.

Int J Dermatol Venereol

Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College, and Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA.

Published: June 2021

Objective: Well-defined germ-line mutations in the gene are associated with syndromic multiple basal cell carcinomas (BCCs). Here, we used whole exome sequencing (WES) to identify the role of patched-1 in patients with multiple, unusually large BCCs.

Methods: A 72-year old patient presenting with numerous BCCs progressing to large ulcerating lesions was enrolled. WES was used to identify the pathogenic gene locus.

Results: Genetic work-up by WES identified a homozygous nonsense mutation in the tumor tissue but not present in her blood cells or in non-lesional skin. In addition, heterozygous missense mutations were identified in three cancer-associated genes (, and ) in blood cells as well as in lesional and non-lesional skin. We also tested systemic immune therapy as a potentially beneficial approach to treat patients with numerous large BCCs on scatted areas of involvement. A rapid and sustained response to nivolumab was noted, suggesting that it is an efficacious drug for long-term therapeutic outcome.

Conclusion: , , and may potentially contribute to the synergistic oncogene driven malignant transformation manifesting as multiple, unusually large BCCs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265835PMC
http://dx.doi.org/10.1097/JD9.0000000000000170DOI Listing

Publication Analysis

Top Keywords

numerous large
8
large ulcerating
8
basal cell
8
cell carcinomas
8
immune therapy
8
wes identify
8
multiple unusually
8
unusually large
8
blood cells
8
non-lesional skin
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!